The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica
Abstract
We explored the role of interleukin 1 (IL-1) in two models of pulmonary fibrosis (PF), elicited in mice by the intra-tracheal instillation of bleomycin or silica. In both models, administration of IL-1 receptor antagonist (IL-1ra) by an osmotic minipump implanted i.p., at a rate of 0.5 microgram/h, completely prevented the collagen deposition, as evaluated by the lung hydroxyproline content on day 15 after instillation. IL-1ra had little or no influence on the number of cells recovered from the broncho-alveolar lavage. Study of histological sections suggests that IL-1ra globally decreased the proportion of damaged lung and particularly in silica the formation of nodules with a rich content in collagen fibrils. IL-1ra was also effective in reducing the lung hydroxyproline content when given on day 25 after instillation of bleomycin or silica, indicating that it may reverse established PF. This study indicates that IL-1ra might be useful for the treatment of incipient or established pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, in a mouse model of bleomycin-or silica-induced pulmonary fibrosis, treatment with IL-1 receptor antagonist (IL-1ra) reduces the proportion of damaged lung (25).”
From Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica (2008) · cites this paper as [25]
Citations
Cites
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,849
Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E. L., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,084
Self-citationInterleukin-1 receptor antagonist reduces mortality from endotoxin shock
OHLSSON, K., Björk, P., Bergenfeldt, M., Hageman, R. J. J., & Thompson, R. C. (1990) · Nature · doi:10.1038/348550a0 · Cited by 848
Self-citationInterleukin 1, a potential regulator of fibroblast proliferation.
Schmidt, J. A., Mizel, S. B., Cohen, D. A., & Green, I. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.5.2177 · Cited by 830
Philip, R., & Epstein, L. B. (1986) · Nature · doi:10.1038/323086a0 · Cited by 762
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro
Dinarello, C. A., & Thompson, R. C. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90142-g · Cited by 719
Self-citationFibrogenic cytokines: the role of immune mediators in the development of scar tissue
Kovacs, E. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90107-5 · Cited by 585
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
Piguet, P. F., Collart, M. A., Grau, G. E., Kapançi, Y., & VASSALLI, P. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.3.655 · Cited by 583
Self-citationCollart, M. A., Belin, D., Vassalli, J. D., Kossodo, S. D., & VASSALLI, P. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.6.2113 · Cited by 524
Khalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505
Research works printed but not linked: 1
- Thrall, 1979, Bleomycin-induced pulmonary fibrosis in the rat, Am J Pathol, 95, 117
Cited by
Sorted by citations
Items 101–200 of 215
Maekawa, T., Kato, S., Kawamura, T., Takada, K., Sone, T., Ogata, H., Saito, K., Izumi, T., Nagao, S., Takano, K., et al. (2019) · Blood · doi:10.1182/blood.2019000051 · Cited by 41
Sakamoto, H., Zhao, L.-H., Jain, F. A., & Kradin, R. L. (2002) · Experimental and Molecular Pathology · doi:10.1006/exmp.2001.2409 · Cited by 41
Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer
Kawai, K., & Akaza, H. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.6.587 · Cited by 42
Interstitial Lung Disease of Systemic Sclerosis
Silver, R. M. (1995) · International Reviews of Immunology · doi:10.3109/08830189509056718 · Cited by 41
Another One Fights the Dust: Targeting the NLRP3 Inflammasome for the Treatment of Silicosis
Lam, M., Mansell, A. S., & Tate, M. D. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0545tr · Cited by 40
Interleukin‐1β induces osteopontin expression in pulmonary fibroblasts
Serlin, D. M., Kuang, P. P., Subramanian, M., O'Regan, A. W., Li, X., Berman, J. S., & Goldstein, R. H. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20661 · Cited by 40
Zhao, M., CUI, J.-Z., Cui, Y., LI, R., Tian, Y., SONG, S.-X., Zhang, J., & Gao, J. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1580 · Cited by 39
Tilg, H., Trehu, E., Shapiro, L., Pape, D., Atkins, M. B., Dinarello, C. A., & Mier, J. W. (1994) · Cytokine · doi:10.1016/1043-4666(94)90044-2 · Cited by 38
Induction of tumor necrosis factor-? as a cause of bleomycin-related toxicity
Sleijfer, S., Vujašković, Ž., Limburg, P. C., Koops, H. S., & Mulder, N. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5 · Cited by 37
Potential Role of the Inflammasome-Derived Inflammatory Cytokines in Pulmonary Fibrosis
Biswas, R., Bunderson‐Schelvan, M., & Holian, A. (2011) · Pulmonary Medicine · doi:10.1155/2011/105707 · Cited by 38
Selige, J., Tenor, H., Hatzelmann, A., & Dunkern, T. R. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22037 · Cited by 34
Idiopathic pulmonary fibrosis: is it a familial disease?
Allam, J. S., & LIMPER, A. H. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000239546.24831.61 · Cited by 33
Gulumian, M. (1999) · Springer eBooks · doi:10.1007/978-1-4615-5097-6_8 · Cited by 33
Pulmonary toxicity of indium‐tin oxide production facility particles in rats
Badding, M. A., Fix, N. R., Orandle, M. S., Barger, M. W., Dunnick, K. M., Cummings, K. J., & Leonard, S. S. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3253 · Cited by 32
Failla, M., Genovese, T., Mazzon, E., Fruciano, M., Fagone, E., Gili, E., Barera, A., Rosa, C. L., Conte, E., Crimi, N., et al. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0438oc · Cited by 32
Current understanding of chemokine involvement in allograft transplantation
Melter, M., McMahon, G. M., Fang, J., Ganz, P., & Briscoe, D. M. (1999) · Pediatric Transplantation · doi:10.1034/j.1399-3046.1999.00023.x · Cited by 32
Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era
Taparra, K., Liu, H., Polley, M. C., Ristow, K. M., Habermann, T. M., & Ansell, S. M. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1663419 · Cited by 30
Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice
Izbicki, G., Or, R., Christensen, T. G., Segel, M. J., Fine, A., Goldstein, R. H., & Breuer, R. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00107.2002 · Cited by 29
Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis.
Lewthwaite, J. C., Blake, S. M., Thompson, R. C., Hardingham, T., & Henderson, B. E. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.7.591 · Cited by 29
Self-citationGajda-Deryło, B., Stahnke, T., Struckmann, S., Warsow, G., Birke, K., Birke, M. T., Hohberger, B., Ręjdak, R., Fuellen, G., & Jünemann, A. G. M. (2019) · Bioscience Reports · doi:10.1042/bsr20181894 · Cited by 28
Inherited interstitial lung disease
Garcia, C. K., & Raghu, G. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.05.001 · Cited by 27
Oliveira, F. M. S., Matias, P. H. D. P., Kraemer, L. R., Gazzinelli-Guimarães, A. C., Vieira-Santos, F., Amorim, C. C. O., Nogueira, D. S., de Freitas, C. S., Caliari, M. V., Bartholomeu, D. C., et al. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007896 · Cited by 28
The lung as a target organ in patients with hematologic disorders.
Poletti, V. E., Salvucci, M., Zanchini, R., Molinari, A. L., Zuffa, E., Poletti, G., & Zaccaria, A. (2000) · PubMed · Cited by 26
Alveolar type II cells inhibit fibroblast proliferation: role of IL-1α
Portnoy, J., Pan, T., Dinarello, C. A., Shannon, J. M., Westcott, J. Y., Zhang, L., & Mason, R. J. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00102.2005 · Cited by 26
Gulumian, M. (1999) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006918212866 · Cited by 26
Winters, C. J., Koval, O. M., Murthy, S., Allamargot, C., Sebag, S. C., Paschke, J. D., Jaffer, O. A., Carter, A. B., & Grumbach, I. M. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00132.2015 · Cited by 25
Association of cytokine gene polymorphisms in CWP and its severity in Turkish coal workers
Ateş, İ., Suzen, H. S., Yücesoy, B., Tekin, İ. Ö., & Karakaya, A. (2008) · American Journal of Industrial Medicine · doi:10.1002/ajim.20632 · Cited by 25
Furuyama, A., Hosokawa, T., & Mochitate, K. (2008) · Matrix Biology · doi:10.1016/j.matbio.2008.02.005 · Cited by 24
Hagaman, D. D., Okayama, Y., D’Ambrosio, C., Prussin, C., Gilfillan, A. M., & Metcalfe, D. D. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.25.6.4541 · Cited by 24
Nakama, K., Miyazaki, Y., & Nasu, M. (1998) · Experimental Lung Research · doi:10.3109/01902149809046054 · Cited by 24
Baker, D. W., Tsai, Y., Weng, H., & Tang, L. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.03.011 · Cited by 23
Serum Cytokine in Response to Chemo-Radiotherapy for Hodgkin's Disease
Villani, F., Busia, A., Villani, M., Vismara, C. S., Viviani, S., & Bonfante, V. (2008) · Tumori Journal · doi:10.1177/030089160809400605 · Cited by 23
Blocking interleukin-1 receptors
Dinarello, C. A. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02593903 · Cited by 24
Modulation of Silica-Induced Pulmonary Toxicity by Dexamethasone-Containing Liposomes
DiMatteo, M., & Reasor, M. J. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8057 · Cited by 23
Chen, W., Luo, J. F., Yuan, Y., Hoyle, R. D., Liu, W., Borst, R., Kazani, S. D., Shikatani, E. A., Erpenbeck, V. J., Pavord, I. D., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001245 · Cited by 22
Divekar, A., Khanna, D., Abtin, F. G., Maranian, P., Saggar, R., Saggar, R., Fürst, D. E., & Singh, R. R. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.08.010 · Cited by 22
Zhou, T., Rong, Y., Liu, Y., Zhou, Y., Guo, J., Cheng, W., Wang, H., & Chen, W. (2012) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e31824525ab · Cited by 22
Interleukin pattern of Apert fibroblasts in vitro
Bodo, M., Carinci, F., Baroni, T., Becchetti, E., Bellucci, C., Giammarioli, M., Pezzetti, F., Tognon, M. G., & Carinci, P. (1998) · European Journal of Cell Biology · doi:10.1016/s0171-9335(98)80072-1 · Cited by 22
CHARACTERISTICS OF THE ACUTE-PHASE PULMONARY RESPONSE TO SILICA IN RATS
DiMatteo, M. (1996) · Journal of Toxicology and Environmental Health · doi:10.1080/009841096161951 · Cited by 22
New strategies for treatment of pulmonary fibrosis.
Phan, S. H. (1995) · Thorax · doi:10.1136/thx.50.4.415 · Cited by 21
Animal models of silicosis: fishing for new therapeutic targets and treatments
Martínez‐López, A., Candel, S., & Tyrkalska, S. D. (2023) · European Respiratory Review · doi:10.1183/16000617.0078-2023 · Cited by 20
Salum, K. C. R., de Castro, M. C. S., Nani, Â. S. F., & Kohlrausch, F. B. (2020) · Inhalation Toxicology · doi:10.1080/08958378.2020.1825569 · Cited by 18
Muc1 deficiency exacerbates pulmonary fibrosis in a mouse model of silicosis
Kato, K., Zemskova, M. A., Hanss, A. D., Kim, M. M., Summer, R. S., & Kim, K. C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.047 · Cited by 18
Novel therapy in the treatment of scleroderma
Wigley, F. M., & Sule, S. D. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.1.31 · Cited by 18
NLRP3 deficiency abrogates silica-induced neutrophil infiltration, pulmonary damage and fibrosis
Lam, M., Barry, K. T., Hodges, C. J., Harpur, C. M., Ong, J. D. H., Rosli, S., West, A. C., Dousha, L. F., Hertzog, P. J., Mansell, A. S., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03192-y · Cited by 17
Sakai, T., Takagaki, H., Yamagiwa, N., Ui, M., Hatta, S., & Imai, J. (2021) · Antioxidants · doi:10.3390/antiox10091398 · Cited by 17
Blake, T. L., DiMatteo, M., Antonini, J. M., McCloud, C. M., & Reasor, M. J. (1996) · Experimental Lung Research · doi:10.3109/01902149609074021 · Cited by 17
The role of interleukin -1 family in fibrotic diseases
Wang, H., Wu, J., Li, M., Bai, Y., & Liu, J. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156161 · Cited by 16
Zhang, Y., Hong, S., Zhang, Q., Su, Z., Hu, G., Wang, T., Yu, S., Yuan, F., Zhu, X., & Jia, G. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.131294 · Cited by 16
Bleomycin therapy of experimental disseminated candidiasis in mice
Graybill, J. R., Bocanegra, R. A., Fothergill, A. W., & Rinaldi, M. G. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.816 · Cited by 16
Chen, J., Ziboh, V. A., & Giri, S. N. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36516-4 · Cited by 16
kiki, S. M. E., Mansour, H. H., Anis, L. M., Youssef, H. M. G., & Kamal, M. M. (2021) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2021.1934765 · Cited by 15
Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacological control
Eugui, E. M. (2002) · Transplantation Proceedings · doi:10.1016/s0041-1345(02)03539-x · Cited by 15
Respiratory Toxicity of Polyhexamethylene Guanidine Phosphate Exposure in Zebrafish
Oh, H., Kim, C., Ryu, B., Kim, U., Kim, J., Lee, J.-M., Lee, B., Moon, J., Jung, C., & Park, J. (2018) · Zebrafish · doi:10.1089/zeb.2018.1571 · Cited by 14
Interleukin 1α and 1β gene variations are associated with tuberculosis in silica exposed subjects
Salum, K. C. R., de Castro, M. C. S., Moreira, V. B., Nani, Â. S. F., & Kohlrausch, F. B. (2019) · American Journal of Industrial Medicine · doi:10.1002/ajim.23066 · Cited by 14
Expression of the interleukin 1 receptor antagonist in the normal human cornea
Torres, P. F., de Vos, A. F., van der Gaag, R., & Kijlstra, A. (1994) · Ocular Immunology and Inflammation · doi:10.3109/09273949409057079 · Cited by 13
Lin, C.-T., Lee, S., Chen, C.-Y., Chen, C., Lin, C.-P., & Huang, H. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000801902158 · Cited by 13
Interleukin-1 receptor antagonist [IL-1F3]
Arend, W. P., & EVANS, C. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50032-6 · Cited by 12
Bombesin Down Modulates Pulmonary Fibrosis Elicited in Mice by Bleomycin
Piguet, P. F., Vesin, C., & Thomas, F. (1995) · Experimental Lung Research · doi:10.3109/01902149509068829 · Cited by 12
Self-citationToward targeted treatments for silicosis
Barnes, H., Lam, M., Tate, M. D., & Hoy, R. F. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001020 · Cited by 11
Mesenchymal Stromal Cell-Based Therapies for Chronic Lung Disease of Prematurity
Strueby, L., & Thébaud, B. (2016) · American Journal of Perinatology · doi:10.1055/s-0036-1586115 · Cited by 10
A recombinant IL-1β vaccine attenuates bleomycin-induced pulmonary fibrosis in mice
Li, H., Li, Q., Hao, Z., Zhang, L., Zhang, L., Zhu, L., Huo, Y., Tian, H., He, L., & Hao, Z. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.091 · Cited by 9
Inflammasome in the Pathogenesis of Pulmonary Diseases
Xu, F., Wen, Z., Shi, X., & Fan, J. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_6 · Cited by 9
Inflammatory Cytokines and Lung Toxicity
Laskin, D. L., Sunil, V. R., Laumbach, R. J., & Kipen, H. M. (2007) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-350-9_6 · Cited by 9
Leinardi, R., Sanchez-Calero, C. L., & Huaux, F. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.887228 · Cited by 8
Pathogenesis and Mechanisms of Asbestosis and Silicosis
Perkins, T. N., Peeters, P. M., Wouters, E. F. �., Reynaert, N. L., & Mossman, B. T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05308-9 · Cited by 7
Veno-Venous Extracorporeal Membrane Oxygenation Use in the Treatment of Bleomycin Pulmonary Toxicity
Shah, A. M., Pasrija, C., Kronfli, A. P., Wehman, B. P., Griffith, B. P., Sánchez, P. G., Garcia, J. P., & Kon, Z. N. (2017) · Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery · doi:10.1097/imi.0000000000000340 · Cited by 7
Katagiri, A., Morimoto, S., Nakiri, Y., Nakano, S., Mitsuo, A., Suzuki, J., Amano, H., Nozawa, K., Asano, M., Tokano, Y., et al. (2008) · Modern Rheumatology · doi:10.3109/s10165-008-0090-8 · Cited by 7
Wanderer, A. A. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.41.2.246 · Cited by 5
The mechanisms of idiopathic pulmonary fibrosis: can we see the elephant?
Gibson, K. F., & Kaminski, N. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.08.002 · Cited by 5
Dasatinib suppresses particulate-induced pyroptosis and acute lung inflammation
Pan, Y., Ikoma, K., Matsui, R., Nakayama, A., Takemura, N., & Saitoh, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1250383 · Cited by 6
Neuro-immune interactions during development of pulmonary fibrosis
Jain, A., & Yu, J. (2017) · Pulmonary and Critical Care Medicine · doi:10.15761/pccm.1000138 · Cited by 4
Asbestos‐Induced Chronic Inflammation and Cancer
Napolitano, A., Jube, S., Gaudino, G., Pass, H. I., Carbone, M., & Yang, H. (2014) · Wiley eBooks · doi:10.1002/9781118826621.ch16 · Cited by 4
IL-1RA autoantibodies: insights into mechanisms and associated diseases
Bouayad, A. (2024) · American Journal of Translational Research · doi:10.62347/ntvu5728 · Cited by 3
Katagiri, A., Morimoto, S., Nakiri, Y., Nakano, S., Mitsuo, A., Suzuki, J., Amano, H., Nozawa, K., Asano, M., Tokano, Y., et al. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0090-8 · Cited by 7
Die Bedeutung von Zytokinen und Wachstumsfaktoren bei fibrosierenden Lungenerkrankungen
Kolb, M. R. J., & Schmidt, M. (2003) · Pneumologie · doi:10.1055/s-2003-37153 · Cited by 3
Novel Strategies to Prevent, Mitigate or Reverse Radiation Injury and Fibrosis
Montay‐Gruel, P., Boivin, G., & Vozenin, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-45594-5_4 · Cited by 2
Inflammation and Pulmonary Fibrosis
Michael, G., Aslam, I., & Simon, P. (2012) · InTech eBooks · doi:10.5772/25569 · Cited by 2
Molecular and Cellular Responses to Asbestos Exposure
Atkinson, M. A. (2005) · CRC Press eBooks · doi:10.1201/9781420038149.ch4 · Cited by 2
Kolb, M. R. J., Xing, Z., & Gauldie, J. (2002) · Elsevier eBooks · doi:10.1016/b978-012079028-9/50105-8 · Cited by 2
Bassett, D. J. P., & Bhalla, D. K. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4535-4_5 · Cited by 2
Tissue Engineering of Internal Medicine for Regeneration Therapy of Chronic Fibrotic Diseases
Yamamoto, M., & Tabata, Y. (2008) · Cited by 1
Inflammatory Markers Involved in the Pathogenesis of Dupuytren's Contracture
Cates, W. T., Denbeigh, J. M., Salvagno, R. T., Kakar, S., van Wijnen, A. J., & Eaton, C. (2024) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2024052889 · Cited by 2
(1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.6.501-a · Cited by 1
Cytokines with Immunosuppressive Capacities
Luger, T. A., & Böhm, M. (1997) · Springer eBooks · doi:10.1007/978-3-642-60752-3_10 · Cited by 1
Regulation of silica-induced pulmonary inflammation
Biswas, R. (2014) · ProQuest Demo Repository · Cited by 1
Korthagen, N. M. (2012) · Utrecht University Repository (Utrecht University)
Lung inflammation, fibrosis, and the concept of fibroblast heterogeneity
Barth, R. K., Baecher‐Allan, C., Linares, A., Suchkova, V. N., Sukhikh, G. T., Grechko, G. K., Blidchenko, Y., Коган, Е. А., & Phipps, R. P. (1996) · Advances in structural biology · doi:10.1016/s1064-6000(96)80009-3
Role of scavenger receptor MARCO in particle uptake and lung inflammation
Thakur, S. A. (2008) · The Mathematics Enthusiast
Pulmonary lesions due to drug therapy of Hodgkin's lymphoma
Даниленко, А. А., & Шахтарина, С. В. (2013) · PULMONOLOGIYA · doi:10.18093/0869-0189-2013-0-1-95-100
Kolb, M. R. J., Xing, Z., Ask, K., & Gauldie, J. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374001-4.00029-8 · Cited by 1
Zhou, T., Cui, X., Zhou, Y., Guo, J., Rong, Y., & Chen, W. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.12.017
Aquaporin in bleomycin induced lung injury
Jang, A., Park, J., Lee, J.-H., Park, S., Kim, D.-J., Uh, S.-T., Kim, Y., & Park, C. (2006) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2006.60.3.330
Kamal, R. N., Molteni, A., Zoubine, M. N., Norkin, M., Reppert, S., Xue, Y., Baybutt, R. C., Herndon, B., & Shnyra, A. (2004) · Nutrition Research · doi:10.1016/j.nutres.2004.06.005
Pathogenesis and treatment of chemical-induced lung injury
Wigenstam, E. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Rossi, G. P., & Agostini, C. (2009)
Immune-inflammatory ffunctions o of ffibroblasts
Jordana, M., Särnstrand, B., & Ramis, I. (1994)
Environment and the Role of Inflammation in Chronic Pulmonary Diseases
Yao, H., & Rahman, I. (2011) · Oxidative stress and disease · doi:10.1201/b11014-4
Inflammasome and Lung Pathologies
Ryffel, B., Togbe, D., & Couillin, I. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0148-5_11
Pathogenesis of Fibrosis—The Lung as a Model
Jefferies, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00019-0
Metadata
- Authors
- Piguet, P. F., Vesin, C., Grau, G. E., & Thompson, R. C.
- Affiliations
- University of Geneva (CH)
- Corresponding author
- Piguet, Pierre F.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 1993-01
- Volume
- 5
- Issue
- 1
- Pages
- 57-61
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2001796665
- Cited by
- 215
- References
- 24
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 2 · 2021: 7 · 2020: 2 · 2019: 9 · 2018: 5 · 2017: 3 · 2016: 7 · 2015: 8 · 2014: 5 · 2013: 6 · 2012: 10
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cytokine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- interleukin-1 receptor antagonist, pulmonary fibrosis, bleomycin-induced lung injury, silica-induced lung injury, interleukin-1, collagen deposition, hydroxyproline, lung hydroxyproline, pulmonary nodules, bronchoalveolar lavage, anti-inflammatory therapy
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Hydroxyproline, Interleukin-1, Lung, Mice, Inbred CBA, Mice, Inbred C57BL, Pulmonary Fibrosis, RNA, Messenger, Silicon Dioxide, Tumor Necrosis Factor-alpha, Receptors, Interleukin-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review